#32026R1306EU authorises cRG-I carrot extract as a novel food
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The regulation allows rhamnogalacturonan-I enriched carrot extract, known as cRG-I, to be sold in the EU as a novel food. It updates the EU novel foods list so the ingredient can be used in approved food categories, food supplements, foods for special medical purposes, and total diet replacement products for weight control. Food and supplement companies can now use the ingredient if they follow the authorised conditions of use. The authorisation is especially relevant for businesses developing functional foods or nutrition products, while use in supplements and certain specialised foods excludes infants and young children.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Authorises cRG-I carrot extract as a novel food in the EU market
- Adds the ingredient to the EU Union list of authorised novel foods
- Sets permitted uses, including limits for supplements and specialised nutrition products
Obligations
What this law requires
Food businesses may place rhamnogalacturonan-I enriched carrot extract (cRG-I) on the EU market as a novel food only where it is authorised and included in the Union list of novel foods under Regulation (EU) 2017/2470 as amended.
Food and supplement companies using cRG-I must comply with the authorised conditions of use set out in the amended Union list of novel foods, including the permitted food categories and maximum use levels applicable to those categories.
Food supplements containing cRG-I must not be intended for infants or young children, because the authorised use in food supplements excludes those population groups.
Foods for special medical purposes containing cRG-I must not be intended for infants or young children, because the authorised use in those specialised foods excludes those population groups.
Total diet replacement products for weight control containing cRG-I must comply with the authorised use conditions and must not be marketed for infants or young children.